News & Updates

Use of vedolizumab as maintenance treatment in children with inflammatory bowel disease (IBD) results in sustained steroid-free remission, with an acceptable safety profile, according to the results of the 54-week follow-up of the VedoKids Study presented at ESPGHAN 2024.

The risk of critical COVID-19 is highest among infants and adolescents, children with multiple comorbidities, those with a history of prematurity, diabetes, obesity, severe immunocompromise, and those with cardiovascular, neurologic, or chronic lung diseases, reveals a study presented at PAS 2024.

Prophylactic interferon-alpha (IFN-α) administered intranasally slashed the incidence of COVID-19 by almost half in a cohort of cancer patients in the C-SMART study.